Sartorius Stedim Biotech

Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
  • TickerDIM
  • ISINFR0013154002
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

SARTORIUS STEDIM BIOTECH sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of SARTORIUS STEDIM BIOTECH (FR), a company active in the Medical Supplies industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 1 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date November 2, 2018, the closing price was EUR 112.30 and its potential was estimated at EUR 122.08.

Jérôme VINERIER

Short term view - SARTORIUS STEDIM BIOTECH : The background trend is clearly bullish.

The background trend is clearly bullish. The recent fall is a consolidation that may be interrupted as it approaches de €97.70. The next target is at €120.50. The trend would be invalidated below the support at €80.80.

Jérôme VINERIER

Analyse court terme - SARTORIUS STEDIM BIOTECH : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. La baisse récente est une consolidation qui peut s'interrompre à l'approche de 97,70 €. Le prochain objectif est à 120,50 €. La tendance serait invalidée sous le support à 80,80 €.

Matthieu DRIOL

Analyse court terme - SARTORIUS STEDIM BIOTECH : Baisse en cours.

La tendance est haussière. La baisse en cours s'apparente à une consolidation. Le support à 97,70 € pourrait relancer le mouvement haussier vers 107,20 €. La rupture de 81,05 € mettrait la tendance en danger.

Matthieu DRIOL

Short term view - SARTORIUS STEDIM BIOTECH : Falling.

The trend is bullish. The current fall looks like a consolidation. The support at €97.70 could cause a bullish reaction towards €107.20. The break of €81.05 would endanger the trend.

Christophe-Raphaël Ganet

Sartorius Stedim Biotech : Q3 2018: ahead of our expectations – Forecasts and target price lifted to € 90

>Sharp rebound in sales and EBITDA - Q3 2018 sales totalled € 310.4m (+19.5% and +18.8% l-f-l) and EBITDA reached € 88.6m, up 28.8%.Growth breaks down as follows: North America - Q3: +33% and +29% l-f-l (vs +8% and +15.3% l-f-l at end-H1) – Europe Q3: +10.4% and +11.2% l-f-l (vs +8.1% and +9.1% l-f-l at end-H1) – Asia-Pacific: Q3: +17.4% and +17.4% l-f-l (vs +4.1% and +8.9% l-f-l at end-H1).9M 2018 sales at constant currency rose 13.8%, to € 896.1m (+11.4% r...

Christophe-Raphaël Ganet

Sartorius Stedim Biotech : T3 2018 : supérieur à notre attente – Prévisions et OC relevés à 90 €

>Fort rebond du CA et de l’EBITDA - Le CA T3 se monte à 310.4 M€ (+19.5% et +18.8% lfl.) et l’EBITDA à 88.6M€, en progression de 28.8%.La croissance se découpe comme suit : Amérique du Nord T3 : +33% et +29% lfl (vs +8% et +15.3% lfl à fin S1) – Europe T3 : +10.4% et +11.2% lfl (vs +8.1% et +9.1% lfl à fin S1) – AsPac : T3 : +17.4% et +17.4% lfl (vs +4.1% et +8.9% lfl à fin S1).A 9 mois, le CA à taux de change constants est en hausse de 13.8%, à 896.1 M€ (+1...

Christophe-Raphaël Ganet

ODDO : Q3 2018 previews: expensive healthcare

>T3: +9.7%e forecast - After growth of around +10% in H1, our forecasts are for growth in the region of 9.7% in Q3.Growth levels are fairly disparate but we can say that the most robust growth levels will likely come from Ipsen, Sartorius Stedim Biotech and bioMérieux. The weakest growth levels will probably be generated by Guerbet, Boiron and Vétoquinol.Virbac has already reported its Q3 results, these were towards the upper end of the forecast range. Q3 pu...

Christophe-Raphaël Ganet

ODDO : Previews T3 2018: chère Santé

>T3: +9.7%e attendus - Après un CA S1 ressortant à environ +10%, nos projections tablent sur une croissance de 9.7%e au T3.Les niveaux de croissance sont assez disparates mais on peut dire que les plus fortes croissances organiques proviendront d’Ipsen, Sartorius Stedim Biotech et bioMérieux. Les plus faibles devraient être publiés par Guerbet, Boiron et Vétoquinol.Le T3 de Virbac a déjà été publié, il était plutôt dans le haut de fourchette des attentes. Le...

Christophe-Raphaël Ganet

ODDO : Q2 2018 postview: momentum fairly positive despite forex - Valuations remain high

>Q2 postview: +8.3% - The Q2 sales publications were broadly satisfactory.The trend for reported growth remained solid at +8.3% (vs +8.9% in Q1 2018).All told, figures came in around 2% above our forecasts, reflecting still solid volumes. Growth trends (around +8%) remained very similar to previous quarters (Q3 2017: +7.5% - Q4 17: +10.7% - T1 18: +8.9%), despite forex, the contribution from external growth remained just as marked. Average organic grow...

A director sold 4,364 shares at 72.567EUR and

A director at Sartorius Stedim Biotech S.A. sold 4,364 shares at 72.567EUR and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The ...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2018

...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 15/10/2018

...

Christophe-Raphaël Ganet ...
  • Michael Foundoukidis
  • Sylvain Goyon, CFA
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 08/28/2018

The ongoing monetary normalisation by the Fed and the imminent prospect of a similar move by the ECB, amid question marks over the real cyclical position on either side of the Atlantic, will likely put rate trends at the top of investors’ list of concerns. We have thus sought to determine the European sectors and stocks with the most exposure to this theme going forward, using weekly 6-month correlations. For a rate increase, the analysis gives a long position on banks, insurance, oil...

SARTORIUS STEDIM BIOTECH sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of SARTORIUS STEDIM BIOTECH (FR), a company active in the Medical Supplies industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 1 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date November 2, 2018, the closing price was EUR 112.30 and its potential was estimated at EUR 122.08.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Proxy Report - 03/04/2018

Oscar-Werner Reif, Volker Niebel et Reinhard Vogt ont démissionné de leurs mandats de Directeurs Généraux Délégués au 31 Décembre 2016. Ils sont désormais respectivement Directeur général délégué à la recherche et au développement, Directeur général délégué aux opérations et systèmes d’information et Directeur général délégué au marketing, aux ventes et aux services. Tout d'abord, notons que malgré une amélioration lors de la précédente assemblée générale, la société n’a pas continué ses efforts en terme d’indépendance du conseil ; avec un taux d'indépendance stagnant à 42,8% selon la définit...

Jehanne Leroy

Etude de l'AG du 04/04/2017

Tout d'abord, la société a SSB a progressé en terme d'indépendance du conseil d'administration puisque suite à la démission de trois des quatre dirigeants présents au conseil, celui-ci présente un taux d'indépendance de 42,8% selon la définition Proxinvest, supérieur au taux de 30% de l'exercice précédent. Ce taux n'est toutefois pas encore suffisant pour satisfaire les recommandations de Proxinvest qui établissent le taux minimum d'indépendance à 50%. Ensuite, l'absence de vote ex-post contraignant sur la rémunération des dirigeants (Loi Sapin 2), constitue un réel manquement de la part de la...

Jérôme VINERIER

Short term view - SARTORIUS STEDIM BIOTECH : The background trend is clearly bullish.

The background trend is clearly bullish. The recent fall is a consolidation that may be interrupted as it approaches de €97.70. The next target is at €120.50. The trend would be invalidated below the support at €80.80.

Jérôme VINERIER

Analyse court terme - SARTORIUS STEDIM BIOTECH : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. La baisse récente est une consolidation qui peut s'interrompre à l'approche de 97,70 €. Le prochain objectif est à 120,50 €. La tendance serait invalidée sous le support à 80,80 €.

Matthieu DRIOL

Analyse court terme - SARTORIUS STEDIM BIOTECH : Baisse en cours.

La tendance est haussière. La baisse en cours s'apparente à une consolidation. Le support à 97,70 € pourrait relancer le mouvement haussier vers 107,20 €. La rupture de 81,05 € mettrait la tendance en danger.

Matthieu DRIOL

Short term view - SARTORIUS STEDIM BIOTECH : Falling.

The trend is bullish. The current fall looks like a consolidation. The support at €97.70 could cause a bullish reaction towards €107.20. The break of €81.05 would endanger the trend.

Matthieu DRIOL

Analyse moyen terme - SARTORIUS STEDIM BIOTECH : La correction gagne en vigueur.

La tendance de fond est clairement orientée à la hausse. La correction en cours gagne en vigueur. Il est trop tôt pour parler de retournement baissier. La tendance serait invalidée sous le support à 72,47 €.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch